AZN Astrazeneca PLC

All AZN filings Filing statistics SEC Website

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Company profile

Ticker

AZN

Exchange

NYSE

CEO

Pascal Soriot

Location

United Kingdom

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Major

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries • Abbott Laboratories • Bristol Myers Squibb • AbbVie • Mylan • Celgene • Endo International ...

Former names

Zeneca Group PLC

SEC CIK

0000901832

AZN stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart AZN financial data

Download latest Excel data (2018 FY) View latest Excel data (2018 FY)

Financial report summary

Competition

Savient Pharmaceuticals • Celldex Therapeutics • Poniard Pharmaceuticals • Aventis • Sicor • Adhera Therapeutics • Brickell Biotech • Spectrum Pharmaceuticals • Geovax Labs • Progenics Pharmaceuticals

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	6th grade Good

New words: Absent, absolute, Academy, Actuarial, Additionally, ADP, Aerosphere, affordability, aforementioned, anaesthetic, analogue, approach, Arabian, Aralez, Aspen, aspirin, assistance, asthma, AZN, BCise, began, Bevespi, biennial, biologic, Biovitrum, bolstered, Brazil, BRCAm, broad, broader, bronchodilator, buying, Bydureon, Byetta, Calquence, carcinoma, Circassia, classification, closure, commentary, competitor, composite, concentrated, conjunction, contrasting, cooperated, COPD, coverage, creditor, CRT, cut, CV, CVMD, CVRM, DAC, Daiichi, demonstrated, diminished, discontinued, Document, dual, Dualkir, duration, EBITDA, education, EGFR, EGFRm, eligibility, eligible, eliminating, emanating, encouraging, endocrine, enzyme, eosinophilic, epidermal, estimate, exceed, exceeding, expiry, exposure, extension, FALCON, false, Fasenra, Faslodex, faster, fell, felt, finalised, Fluenz, Food, France, freeze, grow, growing, hemisphere, highlighting, illustrated, inappropriately, inflammatory, influenza, inhaled, insolvency, Instance, insulin, intensity, IR, Japanese, Kemp, kinase, label, LAMA, legacy, lengthening, Linkbase, linked, Luye, MACE, matured, maximise, MCL, Medicaid, met, metoprolol, mitigated, Movantik, moved, National, nature, nebulisation, necessity, negative, negotiation, NMPA, notable, NRDL, objection, Ono, opportunity, originally, outweighed, overwhelming, PARP, passage, patient, payer, penetration, pharmacy, pilot, placebo, POLO, poly, polymerase, population, predominantly, prevailing, prioritisation, produce, promising, promote, proof, proprietary, published, qui, realized, recede, reclassified, recognition, Recordati, reimbursement, relief, renewed, resource, restriction, retranslation, ribose, rolled, round, Russia, Sankyo, Saudi, Schema, seal, Seloken, shift, Signatory, situation, slowly, Sobi, SoC, stabilised, statin, statistically, statute, strength, study, successful, succinate, symbol, Taxonomy, terminated, track, trend, Trustee, Tudorza, tyrosine, underlined, underlining, underpinned, undertaken, underway, Unfavourable, unrecognised, unsecured, uptake, usage, utilisation, utilised, Valuation, Venezuela, voluntary, weakened, welfare, Western, withdrew, XBRL, Zavicefta, Zomig

Removed: ADS, AG, arm, Astra, California, call, cardiac, closing, created, death, defending, Delaware, Director, distributed, Dow, failure, family, heart, infringement, Jersey, KB, KBI, litigation, LSE, manufacture, Master, Merck, middle, pending, put, ratio, relationship, research, retroactively, Room, settlement, SSE, Stockholm, Street, ultimate, USA, view

From filing 20-F 2018 FY